SK288038B6 - Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection - Google Patents

Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection Download PDF

Info

Publication number
SK288038B6
SK288038B6 SK1710-2000A SK17102000A SK288038B6 SK 288038 B6 SK288038 B6 SK 288038B6 SK 17102000 A SK17102000 A SK 17102000A SK 288038 B6 SK288038 B6 SK 288038B6
Authority
SK
Slovakia
Prior art keywords
weeks
patients
interferon alpha
hcv
treatment
Prior art date
Application number
SK1710-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK17102000A3 (sk
Inventor
Janice K Albrecht
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22151354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK288038(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of SK17102000A3 publication Critical patent/SK17102000A3/sk
Publication of SK288038B6 publication Critical patent/SK288038B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SK1710-2000A 1998-05-15 1999-05-13 Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection SK288038B6 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7956698A 1998-05-15 1998-05-15
PCT/US1999/007037 WO1999059621A1 (en) 1998-05-15 1999-05-13 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection

Publications (2)

Publication Number Publication Date
SK17102000A3 SK17102000A3 (sk) 2001-05-10
SK288038B6 true SK288038B6 (en) 2013-01-02

Family

ID=22151354

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1710-2000A SK288038B6 (en) 1998-05-15 1999-05-13 Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection

Country Status (23)

Country Link
EP (3) EP2305287A1 (no)
JP (2) JP5281726B2 (no)
KR (1) KR100694345B1 (no)
CN (1) CN1230198C (no)
AR (1) AR019551A1 (no)
AT (1) ATE216591T1 (no)
AU (2) AU766597B2 (no)
BR (1) BR9910505A (no)
CA (1) CA2331823A1 (no)
CZ (1) CZ300540B6 (no)
DE (1) DE69901321T2 (no)
DK (1) DK0956861T3 (no)
ES (1) ES2172288T3 (no)
HK (1) HK1021131A1 (no)
HU (1) HU230432B1 (no)
IL (3) IL139220A0 (no)
MY (1) MY129244A (no)
NO (1) NO330715B1 (no)
NZ (1) NZ507621A (no)
PT (1) PT956861E (no)
SK (1) SK288038B6 (no)
TW (1) TWI277424B (no)
WO (1) WO1999059621A1 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2354536A1 (en) * 1998-12-18 2000-06-29 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
HUP0300219A3 (en) * 1999-12-23 2005-07-28 Icn Pharmaceuticals Inc Costa Compositions and methods for l-nucleosides, l-nucleotides, and their analogs
JP4536194B2 (ja) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 安定な注射用製剤
JP2003530847A (ja) * 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CN1315862C (zh) 2000-05-26 2007-05-16 艾登尼科斯（开曼）有限公司 处理黄病毒和瘟病毒的方法和组合物
MXPA03003456A (es) * 2000-10-18 2003-07-14 Schering Corp Terapia de combinacion de ribavirina e interferon alfa pegilado contra el hcv.
ATE481135T1 (de) * 2001-11-09 2010-10-15 Intarcia Therapeutics Inc Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
CN103319554A (zh) 2002-06-28 2013-09-25 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
PL374781A1 (en) 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
PL377342A1 (pl) 2002-11-15 2006-01-23 Idenix (Cayman) Limited Nukleozydy rozgałęzione w pozycji 2' oraz mutacja Flaviviridae
JP2006524227A (ja) * 2003-03-28 2006-10-26 ファーマセット，インク． フラビウイルス科ウイルス感染の治療のための化合物
JP2006528679A (ja) * 2003-04-01 2006-12-21 インターミューン インコーポレイテッド コロナウイルス感染症及びサースを治療するための組成物及び方法
BRPI0409484A (pt) * 2003-04-17 2006-05-02 Ares Trading Sa interferon beta em sìndrome respiratória aguda severa (sars)
CN100503628C (zh) 2003-05-30 2009-06-24 法莫赛特股份有限公司 修饰的氟化核苷类似物
JP2006527268A (ja) * 2003-06-09 2006-11-30 ゲノム インスティチュート オブ シンガポール 臨床的に認められた抗ウイルス剤を用いるｓａｒｓコロナウイルス感染の阻害
EP1660116A4 (en) * 2003-08-13 2008-04-30 Smith Howard J & Ass Pty Ltd METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
WO2006031725A2 (en) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
AP2907A (en) * 2006-01-09 2014-05-31 Romark Lab Lc Viral hepatitis treatment
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
BRPI0814363A2 (pt) 2007-07-25 2015-01-27 Biolex Therapeutics Inc Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
CN102325783A (zh) 2008-12-23 2012-01-18 法莫赛特股份有限公司 嘌呤核苷的合成
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
WO2010075549A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside phosphoramidates
CN102458470B (zh) 2009-05-08 2016-01-20 赛生制药有限公司 作为疫苗增强剂的α胸腺素肽
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
SI3290428T1 (sl) 2010-03-31 2022-01-31 Gilead Pharmasset Llc Tableta, ki obsega kristalinični (S)-izopropil 2-(((S)-(((2R,3R,4R,5R) -5-(2,4-diokso-3,4-dihidropirimidin-1(2H)-il)-4-fluoro-3-hidroksi-4- metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino)propanoat
KR20140035305A (ko) * 2010-10-05 2014-03-21 노파르티스 아게 C형 간염 바이러스 감염의 새로운 치료법
AR084044A1 (es) 2010-11-30 2013-04-17 Pharmasset Inc Compuestos 2’-espiro-nucleosidos
KR20190060879A (ko) * 2011-03-02 2019-06-03 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
HUE036588T2 (hu) 2011-09-16 2018-07-30 Gilead Pharmasset Llc Eljárások HCV kezelésére
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
UA118256C2 (uk) 2013-01-31 2018-12-26 Гіліад Фармассет Елелсі Комбінований склад двох противірусних сполук
SG11201600919UA (en) 2013-08-27 2016-03-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
HUT75533A (en) * 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
ES2214551T3 (es) * 1995-11-02 2004-09-16 Schering Corporation Terapia de infusion continua de citocinas a baja dosis.
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
AU8782098A (en) 1997-08-13 1999-03-08 Boston Scientific Limited Loading and release of water-insoluble drugs
DK1136075T3 (da) * 1997-09-21 2003-04-28 Schering Corp Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion

Also Published As

Publication number Publication date
JP5281726B2 (ja) 2013-09-04
CN1230198C (zh) 2005-12-07
AU766597B2 (en) 2003-10-16
PT956861E (pt) 2002-08-30
EP0956861B1 (en) 2002-04-24
IL207259A0 (en) 2010-12-30
HK1021131A1 (en) 2000-06-02
NO20005755L (no) 2001-01-12
ATE216591T1 (de) 2002-05-15
AU2005220271A1 (en) 2005-11-03
NO330715B1 (no) 2011-06-20
BR9910505A (pt) 2001-01-02
AU2005220271B9 (en) 2010-12-09
CN1309568A (zh) 2001-08-22
TWI277424B (en) 2007-04-01
EP1213029A1 (en) 2002-06-12
KR100694345B1 (ko) 2007-03-12
IL207259A (en) 2016-08-31
DE69901321T2 (de) 2002-12-12
IL139220A (en) 2013-02-28
HUP0103423A3 (en) 2003-11-28
EP2305287A1 (en) 2011-04-06
CZ300540B6 (cs) 2009-06-10
ES2172288T3 (es) 2002-09-16
IL139220A0 (en) 2001-11-25
EP0956861A1 (en) 1999-11-17
CZ20004177A3 (cs) 2001-04-11
WO1999059621A1 (en) 1999-11-25
JP2002515453A (ja) 2002-05-28
KR20010043624A (ko) 2001-05-25
NZ507621A (en) 2002-11-26
AU2005220271B8 (en) 2010-11-18
DK0956861T3 (da) 2002-07-01
SK17102000A3 (sk) 2001-05-10
DE69901321D1 (de) 2002-05-29
HU230432B1 (hu) 2016-06-28
AU2005220271B2 (en) 2005-11-03
CA2331823A1 (en) 1999-11-25
NO20005755D0 (no) 2000-11-14
HUP0103423A2 (hu) 2002-01-28
JP2011173898A (ja) 2011-09-08
AU3860099A (en) 1999-12-06
AR019551A1 (es) 2002-02-27
MY129244A (en) 2007-03-30

Similar Documents

Publication Publication Date Title
SK288038B6 (en) Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection
US6472373B1 (en) Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
TW568787B (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US20020127203A1 (en) Ribavirin-pegylated interferon alfa HCV combination therapy
US6824768B2 (en) Ribavirin-pegylated interferon alfa induction HCV combination therapy
EP1140143A2 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
WO2000037097A1 (en) Ribavirin-interferon alfa induction hcv combination therapy
MXPA00011198A (en) Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection
MXPA01006161A (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
CZ2000788A3 (cs) Použití ribavirinu pro výrobu farmaceutických prostředků, použití interferonů alfa pro výrobu farmaceutických prostředků a farmaceutické výrobky
MXPA98007284A (en) Combination therapy to eradicate vhc-rna detectable in patients who have infection of hepatitis c cron
AU2005218024A1 (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection

Legal Events

Date Code Title Description
TC4A Change of owner's name

Owner name: MERCK SHARP & DOHME CORP., RAHWAY, NJ, US

Effective date: 20121108

MK4A Expiry of patent

Expiry date: 20190513